Vortioxetine for thinking problems from ALK lung cancer treatment
Part of Cancer, Lungs & breathing, Mental health clinical trials.
This trial tests whether a medication called vortioxetine can help improve memory, focus, and thinking problems caused by lorlatinib, a drug used to treat ALK-positive lung cancer. You would take vortioxetine alongside your current cancer treatment to see if it helps your brain function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with ALK-positive or ROS1-positive non-small cell lung cancer (a type of lung cancer), stage 3B or 4
- You are currently taking lorlatinib as your cancer treatment
- You are experiencing thinking, memory, or focus problems that your doctor believes are caused by lorlatinib
- You are 18 years or older and in reasonably good health (able to do light activities)
- Your doctor expects you to live at least 6 months longer
- You can speak, read, and understand Spanish and complete thinking/memory tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether vortioxetine, a depression medication, can help people who have both depression and episodic migraine (recurring headaches). You'd take vortioxetine for depression while researchers track how it affects both your mood and migraine symptoms.
This trial tests if vortioxetine, an antidepressant, can improve mood symptoms (like depression or anxiety) and thinking abilities in people with frontotemporal dementia (FTD). It also includes healthy volunteers for comparison.
This study looks at how certain targeted therapy drugs for ALK/ROS1-positive lung cancer may affect thinking, memory, mood, and mental health. It aims to build a special care and research path where patients and researchers work together to understand and manage these side effects.
This trial tests whether the antidepressant vortioxetine can help people with newly diagnosed glioblastoma when added to standard radiation and chemotherapy. The goal is to see if it improves mood, quality of life, and possibly treatment outcomes.
This trial tests combining chemotherapy with lorlatinib for people with ALK-positive lung cancer that has spread outside the brain while on lorlatinib. The goal is to see if adding chemo can help control the cancer when it starts growing again.
This study looks at how people with advanced ALK-positive non-small cell lung cancer (NSCLC) respond to the targeted drug lorlatinib. It aims to understand whether local treatments (like radiation or surgery) are needed during therapy. If you have this type of lung cancer and haven't had treatment yet, this study might be an option.
Hear when a new Carcinoma, Non-Small-Cell Lung (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.